Posted by Michael Wonder on 24 Dec 2025
FDA approves Omeros’ Yartemlea - first and only therapy indicated for transplant-associated thrombotic microangiopathy
24 December 2025 - Omeros Corporation today announced that the US FDA has approved Yartemlea (narsoplimab-wuug) for the treatment of haematopoietic stem cell transplant-associated thrombotic microangiopathy, an often-fatal complication of stem-cell transplantation driven by activation of the lectin pathway of complement.
Yartemlea is the first and only approved lectin pathway inhibitor.
